Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

Abstract

The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1. As aberrant activation of signal transducing molecules such as Ras and Raf-1 has been linked with cancer, we examined whether constitutive activation of the 41-/43-kDa MAP kinases is associated with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs. Constitutive activation of the MAP kinases was observed in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation. We also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large number of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue. Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation. In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely associated with the activation of MEK and p90rsk in all the tumor cells examined. These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling molecules upstream of Ras.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Avruch J, Zhang XF and Kyriakis JM. . 1994 Trends Biochem. Sci. 19: 273–283.

  • Bansal A, Ramirez RD and Minna, JD. . 1997 Oncogene 14: 1231–1234.

  • Barbacid M. . 1987 Annu. Rev. Biochem. 56: 779–827.

  • Bos JL. . 1988 Mutation Res. 195: 255–271.

  • Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH and Yancopoulos GD. . 1991 Cell 65: 663–675.

  • Brunet A, Pages G and Pouyssegur J. . 1994 Oncogene 9: 3379–3387.

  • Chatani Y, Tanaka E, Tobe K, Hattori A, Sato M, Tamemoto H, Nishizawa N, Nomoto H, Takeya T, Kadowaki T, Kasuga M and Kohno M. . 1992 J. Biol. Chem. 267: 9911–9916.

  • Chatani Y, Tanimura S, Miyoshi N, Hattori A, Sato M and Kohno M. . 1995 J. Biol. Chem. 270: 30686–30692.

  • Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B, Bosman F and Shaw P. . 1997 Hepatology 25: 1376–1381.

  • Cobb MH and Goldsmith EJ. . 1995 J. Biol. Chem. 270: 14843–14846.

  • Cohen P. . 1992 Trends Biochem. Sci. 17: 409–413.

  • Cooper JA, Sefton BM and Hunter T. . 1984 Mol. Cell. Biol. 4: 30–37.

  • Cowley S, Paterson H, Kemp P and Marshall CJ. . 1994 Cell 77: 841–852.

  • Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J and Rapp UR. . 1994 Trends Biochem. Sci. 19: 474–479.

  • Davis RJ. . 1993 J. Biol. Chem. 268: 14553–14556.

  • Hunter T. . 1995 Cell 80: 225–236.

  • Hunter T. . 1997 Cell 88: 333–346.

  • Iwasaki S, Tsuruoka N, Hattori A, Sato M, Tsujimoto M and Kohno M. . 1995 J. Biol. Chem. 270: 5476–5482.

  • Iwasaki S, Hattori A, Sato M, Tsujimoto M and Kohno M. . 1996 J. Biol. Chem. 271: 17360–17365.

  • Kawada M, Uehara Y, Mizuno S, Yamori T and Tsuruo T. . 1998 Jpn. J. Cancer Res. 89: 110–115.

  • Kawaguchi Y, Takebayashi H, Kakizuka A, Arii S, Kato M and Imamura M. . 1997 Cancer Lett. 116: 53–59.

  • Kohno M. . 1985 J. Biol. Chem. 260: 1771–1779.

  • Li PM, Fukazawa H, Yamamoto C, Mizuno S, Tanaka K, Hori M, Yaginuma S, Saito T and Uehara Y. . 1993 Oncogene 8: 1731–1735.

  • Mansour SJ, Mattern WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF and Ahn NG. . 1994 Science 265: 966–970.

  • Nakatsu Y, Nomoto S, Oh-uchida M, Shimizu K and Sekiguchi M. . 1985 Cold Spring Harbor Symp. Quant. Biol. 51: 1001–1008.

  • Nishida E and Gotoh Y. . 1993 Trends Biochem. Sci. 18: 128–131.

  • Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M and Yoshida, O. . 1995 Cancer Res. 55: 4182–4187.

  • Pawson T. . 1995 Nature 373: 573–580.

  • Ray LB and Sturgill TW. . 1987 Proc. Natl. Acad. Sci. USA 84: 1902–1906.

  • Rossomando A, Wu J, Weber MJ and Sturgill TW. . 1992 Proc. Natl. Acad. Sci. USA 89: 5221–5225.

  • Seger R and Krebs EG. . 1995 FASEB J. 9: 726–735.

  • Serrano M. . 1997 Exp. Cell Res. 237: 7–13.

  • Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T. . 1992 Cancer 69: 277–284.

  • Shimizu K, Goldfarb M, Suard Y, Perucho M, Li Y, Kamata T, Feramisco J, Stavnezer E, Fogh J and Wigler MH. . 1983 Proc. Natl. Acad. Sci. USA 80: 2112–2116.

  • Smith DB and Corcoran LM. . 1990 Current Protocols in Molecular Biology, Vol.2. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K. (eds). Greene Publishing Associates and Wiley-Interscience, John Wiley & Sons: New York pp. 16.7.1–16.7.6.

    Google Scholar 

  • Sporn MB and Todaro GT. . 1980 N. Engl. J. Med. 303: 878–880.

  • Sturgill TW, Ray LB, Erikson E and Maller JL. . 1988 Nature 334: 715–718.

  • Sun H, Charies CH, Lau LF and Tonks NK. . 1993 Cell 75: 487–493.

  • Tanimura S, Chatani Y, Hoshino R, Sato M, Watanabe S, Kataoka T, Nakamura T and Kohno M. . 1998 Oncogene 17: 57–65.

  • Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ and Kelly K. . 1994 Nature 367: 651–654.

  • Yao M, Shuin T, Misaki H and Kubota Y. . 1988 Cancer Res. 48: 6753–6757.

Download references

Acknowledgements

We thank Drs Ei-ichi Tahara, Hidetoshi Tahara, Sakuji Toyama and Mayumi Ono for various tumor cell lines, Dr Michael J Weber for the cDNA for ERK2K52R, and Dr Patrick Hughes for critical reading of the manuscript. This work was supported in part by Grants-in-aid for Scientific Research from the Ministry of Education, Sciences, Sports and Culture of Japan.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoshino, R., Chatani, Y., Yamori, T. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813–822 (1999). https://doi.org/10.1038/sj.onc.1202367

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202367

Keywords

This article is cited by

Search

Quick links